The biotechnology industry has faced many challenges since its inception in the late 1970s. The ability to translate new discoveries
into viable therapies that could be produced on a large scale and delivered to patients across the globe required overcoming
many hurdles. Biopharmaceutical manufacturing, in particular, has presented major challenges, even to the industry's leaders.
In addition to the inherent difficulties associated with a production platform based on molecular and cellular biology, biopharmaceutical
manufacturing always has been subject to the vicissitudes of unpredictable clinical trials, regulatory requirements, product
approvals, and market demand. When we add to this the need to invest in expensive manufacturing facilities before product
approval, the challenges take on the multiple dimensions of technology, logistics, and economics.
Operator preparing to load excipient to process vessel during formulation process (Wyeth Biotech)
Perhaps it is reassuring that corporations, even entire industries, undergo discrete stages of development, from uncertain
beginnings to a more predictable maturity. Eventually, novel and unique technologies evolve to become robust and economically
viable. Although the biopharmaceutical industry is only 30 years old, it has already graduated through several stages of development
and is currently undergoing an important transition. We are on the cusp of a manufacturing renaissance where companies will
have the ability to produce biopharmaceuticals consistently at high yields, respond rapidly to shifts in demand and development
cycles, and lower investment in production infrastructure. These changes are being driven technically, by advances in biological
and process engineering, as well as economically, through facility sharing and utilization. As a result, we believe that the
fundamentals of the biotechnology industry will change dramatically, resulting in product costs and flexibility equal to those
currently achieved for small-molecule pharmaceuticals. Progress in biopharmaceutical manufacturing will have far-reaching
consequences for industry dynamics and competitive strategies. The three drivers for this transition are:
- increased production yields through process development and biological science instead of hardware solutions
- standardization of facilities and processes
- broad implementation of common platform technologies.
A similar transition occurred in the semiconductor industry. The dramatic improvements in semiconductor manufacturing brought
about by facility and process standardization, platform technologies, and scientifically based product improvements, led to
rapid growth and lower costs in that industry beginning in the mid-1980s.
Michael E. Kamarck
GROWTH OF THE BIOTECHNOLOGY INDUSTRY
To get a better idea of where the biotechnology industry is situated on its path toward maturity, let's take a look at its
history so far. The biotechnology industry first emerged with the advent of recombinant DNA technology, a tool that enabled
scientists to envision the mass production of therapeutic proteins. Insulin, human growth hormone, hemophilia proteins, and
erythropoietin were among the first protein products that were developed into biopharmaceuticals, replacing or augmenting
biological pathways that had become dysfunctional through disease. These proteins were followed by the introduction of monoclonal
antibodies, which could act as antagonist drugs, targeting biological molecules in a variety of disease pathways. While both
types of biopharmaceuticals are of continuing importance, monoclonal antibodies have been driving the industry for the past
The early years of biopharmaceutical production saw scientists evolve into engineers, inventing production equipment, control
systems, and analytical technology that simply did not exist in a pharmaceutical industry based on developing medicines from
small chemical compounds. Unlike small-molecule drugs, protein-based drugs were produced by living cells; manufacturing cell
lines had to be established and then grown under conditions that promoted viability and high cell densities. Finally, the
cells needed to be separated from their products and the protein purified aseptically. The core technology used to produce
and purify the protein-based drugs varied among companies and manufacturing plants. In the industry, the initial focus was
on making new products, not production efficiency, and demand quickly outstripped the capacity to supply.